D. E. Shaw & Co., Inc. Omeros Corp Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Omeros Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,576,383 shares of OMER stock, worth $6.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,576,383

Previous 1,677,683 6.04%

Holding current value

$6.7 Million

Previous $5.79 Million 10.57%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.04 - $4.23 $307,952 - $428,499	-101,300 Reduced 6.04%	1,576,383 $6.4 Million
Q1 2024 May 15, 2024	BUY	$2.88 - $4.89 $533,894 - $906,508	185,380 Added 12.42%	1,677,683 $5.79 Million
Q4 2023 Feb 14, 2024	BUY	$1.08 - $3.63 $141,336 - $475,047	130,867 Added 9.61%	1,492,303 $4.88 Million
Q3 2023 Nov 14, 2023	SELL	$2.81 - $5.69 $780,522 - $1.58 Million	-277,766 Reduced 16.95%	1,361,436 $3.98 Million
Q2 2023 Aug 14, 2023	BUY	$4.45 - $7.57 $786,199 - $1.34 Million	176,674 Added 12.08%	1,639,202 $8.92 Million
Q1 2023 May 15, 2023	SELL	$2.48 - $5.22 $709,748 - $1.49 Million	-286,189 Reduced 16.37%	1,462,528 $6.8 Million
Q4 2022 Feb 14, 2023	SELL	$1.75 - $3.96 $457,814 - $1.04 Million	-261,608 Reduced 13.01%	1,748,717 $3.95 Million
Q3 2022 Nov 14, 2022	SELL	$3.09 - $7.46 $458,111 - $1.11 Million	-148,256 Reduced 6.87%	2,010,325 $6.33 Million
Q2 2022 Aug 15, 2022	BUY	$1.92 - $6.28 $618,420 - $2.02 Million	322,094 Added 17.54%	2,158,581 $5.94 Million
Q1 2022 May 16, 2022	SELL	$5.07 - $7.2 $389,548 - $553,204	-76,834 Reduced 4.02%	1,836,487 $11 Million
Q4 2021 Feb 14, 2022	SELL	$5.67 - $8.54 $948,392 - $1.43 Million	-167,265 Reduced 8.04%	1,913,321 $12.3 Million
Q3 2021 Nov 15, 2021	SELL	$13.4 - $16.3 $3.86 Million - $4.7 Million	-288,231 Reduced 12.17%	2,080,586 $28.7 Million
Q2 2021 Aug 16, 2021	SELL	$14.81 - $19.13 $5.08 Million - $6.56 Million	-343,143 Reduced 12.65%	2,368,817 $35.2 Million
Q1 2021 May 17, 2021	SELL	$14.52 - $23.53 $571,289 - $925,787	-39,345 Reduced 1.43%	2,711,960 $48.3 Million
Q4 2020 Feb 16, 2021	BUY	$10.14 - $15.19 $2.33 Million - $3.48 Million	229,331 Added 9.09%	2,751,305 $39.3 Million
Q3 2020 Nov 16, 2020	BUY	$9.57 - $21.32 $5.3 Million - $11.8 Million	553,706 Added 28.13%	2,521,974 $25.5 Million
Q2 2020 Aug 14, 2020	BUY	$12.21 - $16.99 $284,273 - $395,561	23,282 Added 1.2%	1,968,268 $29 Million
Q1 2020 May 15, 2020	BUY	$9.03 - $19.72 $1.44 Million - $3.15 Million	159,835 Added 8.95%	1,944,986 $26 Million
Q4 2019 Feb 14, 2020	SELL	$13.01 - $17.15 $5.47 Million - $7.21 Million	-420,169 Reduced 19.05%	1,785,151 $25.2 Million
Q3 2019 Nov 14, 2019	SELL	$14.55 - $20.56 $1.15 Million - $1.63 Million	-79,223 Reduced 3.47%	2,205,320 $36 Million
Q2 2019 Aug 14, 2019	SELL	$15.0 - $19.62 $4.51 Million - $5.9 Million	-300,895 Reduced 11.64%	2,284,543 $35.8 Million
Q1 2019 May 15, 2019	BUY	$11.65 - $17.72 $7.84 Million - $11.9 Million	673,194 Added 35.2%	2,585,438 $44.9 Million
Q4 2018 Feb 14, 2019	BUY	$10.72 - $16.73 $6.78 Million - $10.6 Million	632,840 Added 49.46%	1,912,244 $21.3 Million
Q3 2018 Nov 14, 2018	BUY	$17.73 - $26.69 $6.61 Million - $9.95 Million	372,877 Added 41.13%	1,279,404 $31.2 Million
Q2 2018 Aug 14, 2018	BUY	$10.79 - $24.44 $8.09 Million - $18.3 Million	749,893 Added 478.75%	906,527 $16.4 Million
Q1 2018 May 15, 2018	SELL	$9.0 - $20.16 $3.06 Million - $6.86 Million	-340,193 Reduced 68.47%	156,634 $1.75 Million
Q4 2017 Feb 14, 2018	BUY	$13.26 - $22.86 $1.51 Million - $2.6 Million	113,546 Added 29.62%	496,827 $9.65 Million
Q3 2017 Nov 14, 2017	BUY	$19.76 - $24.9 $7.57 Million - $9.54 Million	383,281	383,281 $8.29 Million

Others Institutions Holding OMER

# of Institutions

113

Shares Held

25.5M

Call Options Held

317K

Put Options Held

556K

View Full List

About OMEROS CORP

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $267M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

More about OMER

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account